This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related letters  • Related article  • Similar articles in JAMA  Topic Collections  • Radiation Therapy  • Liver/ Biliary Tract/ Pancreatic Diseases  • Alert me on articles by topic

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: Dr Oettle and colleagues¹ reported the results of a multicenter randomized controlled trial of adjuvant chemotherapy with gemcitabine vs observation in patients with resectable pancreatic cancer. They provided the results of a survival analysis based on all eligible patients (intent-to-treat); they also presented a qualified survival analysis based on the population of patients who had received at least 1 complete cycle of gemcitabine, intended to more closely reflect the "true" therapeutic potential of the drug. Besides a large and significant advantage of gemcitabine in delaying the development of recurrent disease, there was a statistically nonsignificant improved survival in the treated group in the intent-to-treat analysis (log-rank P = .06), which reached statistical significance in the qualified analysis (P = .02). However, the potential survival advantage was only seen 2 years after treatment and was more prominent after 5 years, with twice as many survivors in the treated group . . . [Full Text of this Article]

Patrick Maisonneuve, Eng
patrick.maisonneuve@ieo.it
European Institute of Oncology
Milan, Italy

Albert B. Lowenfels, MD
New York Medical College
Valhalla

RELATED LETTERS

Adjuvant Chemotherapy With Gemcitabine for Patients With Resectable Pancreatic Cancer
Anand T. Shivnani
JAMA. 2007;297(23):2581-2582.
EXTRACT | FULL TEXT  

Adjuvant Chemotherapy With Gemcitabine for Patients With Resectable Pancreatic Cancer—Reply
Helmut Oettle
JAMA. 2007;297(23):2582.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer: A Randomized Controlled Trial
Helmut Oettle, Stefan Post, Peter Neuhaus, Klaus Gellert, Jan Langrehr, Karsten Ridwelski, Harald Schramm, Joerg Fahlke, Carl Zuelke, Christof Burkart, Klaus Gutberlet, Erika Kettner, Harald Schmalenberg, Karin Weigang-Koehler, Wolf-Otto Bechstein, Marco Niedergethmann, Ingo Schmidt-Wolf, Lars Roll, Bernd Doerken, and Hanno Riess
JAMA. 2007;297(3):267-277.
ABSTRACT | FULL TEXT